Sun H, Saidi P, Karlanga S, Pinkepank M, Ogurtsova K, Duncan BB, et al. IDF Diabetes Atlas: 2021 global, regional, and country diabetes prevalence estimates and 2045 projections. Diabetes Res Clin Pract. 2022;183:109119.
Olesen KKW, Anand S, Thim T, Gyldenkerne C, Maeng M. Microvascular disease increases the risk of lower extremity amputation: a western Danish cohort study. Eur J Clin Investment 2022;52:e13812.
Rinkel WD, Luyten J, van Dongen J, Kuppens B, van Neck JW, Polider S, Hospital costs for diabetic foot disease treated by a multidisciplinary foot team. Diabetes treatment clinical practice. 2017;132:68–78.
Stern JR, Wong CK, Erovinkina M, Spindler SJ, AS Reference, Panjaki S, et al. Meta-analysis of long-term mortality and associated risk factors after lower extremity amputation. Anne Basque Surgeon. 2017;42:322–7.
Apelqvist J, Larsson J. What is the most effective way to reduce the incidence of diabetic foot amputation? Diabetes Metab Res Rev. 2000;16(Suppl 1):S75–83.
Eason SL, Petersen NJ, Suarez-Almazor M, Davis B, Collins TC. Diabetes, smoking, and the risk of asymptomatic peripheral artery disease: Who should be tested? J Am Board Femme Pract. 2005;18:355–61.
Lange S, Diem C, Darius H, Haberle R, Arenberg JR, Pittlow D, et al. High prevalence and low treatment rates of peripheral artery disease in elderly primary care patients with diabetes. Exp Clin Endocrine Diabetes. 2004;112:566–73.
Murabito JM, D'Agostino RB, Silberschatz H, Wilson WF. Intermittent lameness. Risk profile from the Framingham Heart Study. circulation. 1997;96:44–9.
American Diabetes Association Professional Practice C. 10. Cardiovascular Disease and Risk Management: Standards of Care for Diabetes – 2024. diabetes care. 2024;47:S179–218.
hoi JH, Lee KA, Moon JH, Chon S, Kim DJ, Kim HJ et al. 2023 Diabetes Treatment Guidelines of the Korean Diabetes Association. Diabetes Metatab J. 2023;47:575-594
Yang YS, Kim HL, Kim SH, Moon MK. Lipid management in Korean patients with type 2 diabetes: Consensus statement of the Korean Diabetes Association and the Korean Society of Lipid and Atherosclerosis. Diabetes Metatab J. 2023;47:1–9.
Wong ND, Zhao Y, Quek RGW, Blumenthal RS, Budoff MJ, Cushman M et al. Residual risk of atherosclerotic cardiovascular disease in statin-treated adults: the Multi-Ethnic Study of Atherosclerosis. J Clin Lipidol. 2017;11:1223–33.
Alsheikh Ali AA, Lin JL, Abuljairi P, Ahern D, Kubin JT, Karas RH. Prevalence of low-density lipoprotein cholesterol in patients with coronary heart disease or equivalent risk and with proven controlled low-density lipoprotein cholesterol. This is J Cardiol. 2007;100:1499–501.
LaRosa JC, Grundy SM, Waters DD, Shear C, Barter P, Furchert JC, et al. Intensive lipid lowering with atorvastatin in patients with stable coronary artery disease. N Eng J Med 2005;352:1425–35.
Matfin G, Thorne M. Disagreement on ACCORD-lipid test results. Advanced endocrine meta tab. 2010;1:47–9.
Shin IM, Shishebolu MH, Ansel BJ. High-density lipoproteins as therapeutic targets: a systematic review. jam. 2007;298:786–98.
Rubins HB, Robbins SJ, Collins D, Fai CL, Anderson JW, Elam MB, et al. Gemfibrozil for secondary prevention of coronary heart disease in men with low high-density lipoprotein cholesterol levels. Department of Veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Research Group. N Eng J Med 1999;341:410–8.
Flick MH, Erro O, Harpa K, Heinonen OP, Heinsalmi P, Herro P, et al. Helsinki Heart Study: A primary prevention trial of gemfibrozil in middle-aged men with dyslipidemia. Treatment safety, changes in risk factors, and incidence of coronary heart disease. N Eng J Med 1987;317:1237–45.
Elam M, Lovato L, Ginsberg H. ACCORD Lipid Research: Implications for the Treatment of Dyslipidemia in Type 2 Diabetes. Clinlipidol. 2011;6:9–20.
Keach A, Sims RJ, Barter P, Best J, Scott R, Taskinen MR, et al. Effect of long-term fenofibrate on cardiovascular events in 9795 patients with type 2 diabetes (FIELD study): a randomized controlled trial. Lancet. 2005;366:1849–61.
Kim MK, Han K, Lee SH. Current trends in big data research using South Korea's national health information database. Diabetes Metatab J. 2022;46:552–63.
Marx N, Federici M, Schutt K, Müller-Wieland D, Ajan RA, Antunes MJ, et al. 2023 ESC Guidelines for the Management of Cardiovascular Disease in Patients with Diabetes. Eur Heart J. 2023;44:4043–140.
Kuriki MH, Matsushita K, Aboyans V, Hess CN, Hicks CW, Kwan TW et al Lower extremity peripheral artery disease: contemporary epidemiology, management gaps, and future directions: a scientific statement by the American Heart Association. circulation. 2021;144:e171-91.
Pastori D, Falconeni A, Milanese A, Del Sole F, Menichelli D, Hyatt WR Statins and major extremity adverse events in patients with peripheral arterial disease: a systematic review and meta-analysis. Thromb Hemost. 2020;120:866–75.
Chapman MJ, Ginsburg HN, Amarenko P, Andreotti F, Boren J, Catapano AL, Triglyceride-rich lipoproteins and high-density lipoprotein cholesterol in patients at high risk for other cardiovascular diseases: evidence and guidance for management. Eur Heart J. 2011;32:1345–61.
Keating GM, Ormrod D. Micronized fenofibrate: an updated review of clinical efficacy in the management of dyslipidemia. drugs. 2002;62:1909–44.
Stahls B, Dalongeville J, Orwerks J, Schoonjans K, Reitersdorf E, Furchert JC. Mechanism of action of fibrates on lipid and lipoprotein metabolism. circulation. 1998;98:2088–93.
Brookert E, Dejager S, Chapman MJ. Ciprofibrate therapy normalizes the atherogenic low-density lipoprotein subspecies profile in combined hyperlipidemia. Atherosclerosis. 1993;100:91–102.
Jin L, Hua H, Ji Y, Jia Z, Peng M, Huang S. Anti-inflammatory effects of fenofibrate in the treatment of diseases. Biomol Biomed. 2023;23:376–91.
Libby P, Plutzky J. Inflammation in diabetes: the role of peroxisome proliferator-activated receptor alpha and peroxisome proliferator-activated receptor gamma agonists. This is J Cardiol. 2007;99:B27–40.
Koh KK, Han SH, Quon MJ, Yeal Ahn J, Shin EK. Beneficial effects of fenofibrate to improve endothelial dysfunction and increase adiponectin levels in patients with primary hypertriglyceridemia. diabetes care. 2005;28:1419–24.
Herkeles RS, Diamond JR, Poulter C, Danzil S, Nicolaides AN, Mahmoud S, et al. Cardiovascular outcomes in type 2 diabetes. Double-blind, placebo-controlled study of bezafibrate: St Mary's, Northwick Park, Ealing, Diabetes and Cardiovascular Disease Prevention (SENDCAP) study. diabetes care. 1998;21:641–8.
Rubins HB, Robins SJ, Collins D, Nelson DB, Elam MB, Schaefer EJ, et al. Diabetes, plasma insulin, and cardiovascular disease: Subgroup analysis from the Department of Veterans Affairs High-Density Lipoprotein Intervention Trial (VA-HIT). Arch intern MD. 2002;162:2597–604.
Tenenbaum A, Motro M, Fisman EZ, Tanne D, Boyko V, Behar S. Bezafibrate for secondary prevention of myocardial infarction in patients with metabolic syndrome. Arch intern MD. 2005;165:1154–60.
Group AS, Ginsburg HN, Elam MB, Lovato LC, Krauss JR III, Reiter LA, et al. Effects of lipid combination therapy in type 2 diabetes. N Eng J Med 2010;362:1563–74.
Zhu L, Hayen A, Bell KJL. Legacy effects of add-on fibrate therapy in diabetic patients with dyslipidemia: a secondary analysis of the ACCORDION study. Cardiovascular diabetes. 2020;19:28.
Lee YJ, Song S, Song Y. High-carbohydrate diets and dietary patterns in Koreans and their association with metabolic diseases. Yonsei Med J. 2018;59:834–42.
Deerochanawong C, Kim SG, Chan YC. The role of fenofibrate use in dyslipidemia and associated comorbidities in Asian populations: a narrative review. Diabetes Metatab J. 2024;48:184–95.
Arabic
Dutch
English
French
German
Italian
Portuguese
Russian
Spanish